Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Others

Novo Nordisk CagriSema Pediatric Obesity Trial to Enroll 460 Children

Fineline Cube Dec 3, 2025

Novo Nordisk (NYSE: NVO) is planning to test its experimental obesity drug CagriSema in overweight...

Company Drug

Antengene ATG-022 CLDN18.2 ADC Gets China Nod for Keytruda Combo in Gastric Cancer

Fineline Cube Dec 3, 2025

Antengene Corporation Limited (HKG: 6996) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Drug

MSD MK-2214 Fast Track Alzheimer Data Positive

Fineline Cube Dec 3, 2025

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) released first‑in‑human data for MK-2214 and MK-1167 in...

Policy / Regulatory

China Drug-Price Registration System Launches with First Batch of 10 Products

Fineline Cube Dec 3, 2025

China’s Drug Price Registration System officially launched today with the first batch of 10 drug...

Company Deals

3SBio HK$3.1B Placement Funds R&D Pipeline for 705, 706, 008

Fineline Cube Dec 3, 2025

3SBio Inc. (HKG: 1530) conditionally agreed to place 105,169,500 shares at HK$29.62 per share, raising...

Company Drug

Generate GB-0895 Asthma Phase III Trials to Enroll 1,600 Patients

Fineline Cube Dec 3, 2025

Generate: Biomedicines today announced plans to initiate two global Phase III clinical trials (SOLAIRIA-1 and...

Company Drug

Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE

Fineline Cube Dec 3, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the National Medical Products Administration’s Center for...

Company Deals

New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals

Fineline Cube Dec 3, 2025

Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...

Company Deals Drug

Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment

Fineline Cube Dec 3, 2025

Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI...

Company Medical Device

Roche cobas-liat Whooping-Cough Test Secures FDA Clearance

Fineline Cube Dec 3, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its cobas liat system-based point‑of‑care test for whooping...

Company Drug

Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors

Fineline Cube Dec 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant...

Company Drug

Leads-Biolabs LBL047 Bispecific Secures China IND Approval for SLE

Fineline Cube Dec 2, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the National Medical Products Administration (NMPA)...

Company Deals

Shanghai Bao Pharma IPO HKEX Raises HK$1 Billion for Biotech Pipeline

Fineline Cube Dec 2, 2025

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) successfully listed on the Hong Kong Stock Exchange...

Company Drug

Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval

Fineline Cube Dec 2, 2025

Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141,...

Company Drug

AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China

Fineline Cube Dec 2, 2025

AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list...

Company Drug

Lynk Pharma LNK01006 FDA Approval Targets TYK2 for CNS Diseases

Fineline Cube Dec 2, 2025

Lynk Pharmaceuticals Co., Ltd. announced that its self‑developed TYK2 allosteric inhibitor LNK01006 has received FDA...

Others

FDA Prasad Outlines New Vaccine Approval Process After Covid-19 Safety Analysis

Fineline Cube Dec 2, 2025

Dr. Vinay Prasad, FDA’s chief medical and scientific officer, announced plans to overhaul the vaccine...

Hospital Policy / Regulatory

China Health: Life Expectancy Hits 79 Years as Hospitals Expand and Expenditure Controlled

Fineline Cube Dec 2, 2025

The National Health Commission released the Statistical Bulletin on China’s Health Undertakings 2024, showing China’s...

Company Drug

CANbridge’s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus

Fineline Cube Dec 2, 2025

CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of...

Company Deals

WuXi Biologics CRDMO Qatar MOU Establishes First Middle East Center

Fineline Cube Dec 2, 2025

WuXi Biologics (HKG: 2269) announced it has signed a strategic Memorandum of Understanding (MOU) with...

Posts pagination

1 … 126 127 128 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.